Signals, Powered By EquityPandit
A non-exclusive licensing agreement has been signed by Natco Pharma with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb for manufacturing and selling generic version of Daclatasvir, which is used in the treatment of chronic hepatitis C.
Natco Pharma has said in a BSE filing that “It has signed a non-exclusive, royalty free licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Bristol-Myers Squibb’s chronic hepatitis C medicine Daclatasvir Dihydrochloride (Daclatasvir).”
It further said that “Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.”
